NEW YORK – Sphingotec announced its in vitro diagnostic assay for dipeptidyl peptidase 3 has been CE-IVD marked.
The company has launched the test.
According to the German diagnostic company, the assay, called IB10 Sphingotec DPP3, is the first CE-IVD-marked point-of-care biomarker test that can quantify DPP3 blood plasma levels. DPP3 is a biomarker that can predict outcomes in patients with cardiogenic shock when they are admitted to hospital intensive care units.